BioAlliance Extends Phase III Trial of Herpes Treatment
Posted on: Wednesday, 28 November 2007, 12:00 CST
BioAlliance Pharma has extended its ongoing acyclovir lauriad Phase III trial in the treatment of oral herpes to US. Ten clinical centers have been opened in the country and will join the 40 or so in Australia and Europe already participating in the trial, with a target of 640 patients.
The technology used in the trial, the Lauriad buccal muco-adhesive tablet, has already proved itself in the company's Loramyc product. The healing time of herpes lesions after taking a single acyclovir Lauriad tablet will be compared with placebo. The company is planning to submit market authorization applications in the first half of 2009 in Europe and in the US, subject to additional regulatory requirements.
Furthermore, after successful completion of patient enrolment in the pivotal Phase III clinical trial performed with a view to registering Loramyc in the US, the company is continuing to open additional European centers for its Phase III doxorubicin Transdrug trial in primary liver cancer.
Dominique Costantini, president of the management board at BioAlliance Pharma, said: "With acyclovir lauriad in the US, our objective is to be able to access 60% of the potential market that the product represents."
Source: Datamonitor
Related Articles
- ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
- Spectrum Granted Canadian Approval for Phase III Cancer Trial
- Delcath Resumes Enrollment in Phase III and Phase II Trials
- Auxilium Pharmaceuticals, Inc. Initiates Phase III Trials for AA4500 in Dupuytren's Contracture
- Quigley Pharma's QR-333 Phase IIb Clinical Study Has Commenced; Drug Product and Clinical Trial Sites Prepared for Phase IIb Study of Lead Drug Candidate
- Pfizer Updates Preliminary Results of Torcetrapib/Atorvastatin Clinical Trials As Abstract for Phase 3 Study is Released
- BMS Presents Promising Phase III Hepatitis Data
- CytRx Completes Enrollment in Phase IIa Clinical Trial for ALS; Final Phase IIa Data Expected to Be Reported in Third Quarter 2006
- The Medicines Company Resumes Clevidipine Phase III Program; Phase III Interim Data Review Affirms Safety Profile
- Manhattan Pharmaceuticals Granted FDA Approval to Initiate Phase I Clinical Trials for Oleoyl Estrone; Phase I Trial Expected to Begin in First Quarter 2005
 |
 |
User Comments (0)
RSS Feeds